In this study, our results further demonstrated the prognostic value of B-Myb expression in pan-cancers such as adrenocortical carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, low-grade glioma of the brain, hepatocellular carcinoma, lung adenocarcinoma, mesothelioma, and pancreatic cancer, highly suggesting the necessity for deep investigations on the role of B-Myb in these cancers and the underlying molecular mechanisms. The gene discussed is MYBL2; the disease is adrenal cortex carcinoma.